Impact of quadruple regimen of clarithromycin added to metronidazole- containing triple therapy against helicobacter pylori infection following clarithromycin-containing triple-therapy failure

Helicobacter

Volumn 14, Issue 2, 2009, Pages 91-99

  Ueki, Nobue ^a   Miyake, Kazumasa ^a   Kusunoki, Masafumi ^a   Shindo, Tomotaka ^a   Kawagoe, Tetsuro ^a   Futagami, Seiji ^a   Tsukui, Taku ^a   Inagaki, Hirofumi ^a   Sakamoto, Choitsu ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Clarithromycin resistance; Eradication; Helicobacter pylori; Quadruple therapy; Second line therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; RABEPRAZOLE;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; MAJOR CLINICAL STUDY; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT FAILURE; UREA BREATH TEST; VOMITING;

ADULT; AGED; AMOXICILLIN; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TREATMENT FAILURE;

HELICOBACTER PYLORI;

EID: 62149140495     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2009.00664.x     Document Type: Article

References (42)

1. Miwa H, Sasaki N, Sugano K, et al. Recurrent peptic ulcers in patients with following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter 2004 9 : 9 16.
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002 16 : 167 70.
3. Murakami K, Sato R, Okimoto T, et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003 17 : 119 23.
4. Kaneko F, Suzuki H, Hasegawa N, et al. High prevalence rate for Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. Aliment Pharmacol Ther 2004 20 : 62 7.
5. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007 56 : 1353 7.
6. Hishiya S, Watanabe K, Tokunaga K, et al. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J Gastroenterol 2000 35 : 10 4.
7. Murakami K, Sato R, Okimoto T, et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002 16 : 1933 8.
8. Murakami K, Okimoto T, Kodama M, Sato R, Watanabe K, Fujioka T. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. J Clin Gastroenterol 2008 42 : 139 42.
9. Kawai T, Kawakami K, Kataoka M, et al. Comparison of efficacies of dual therapy and triple therapy using rabeprazole in second-line eradication of Helicobacter pylori in Japan. Aliment Pharmacol Ther 2006 24 : 16 22.
10. Fukuda S, Shimoyama T, Tanaka M, Nakasato F, Fukushi M, Munakata A. Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in Northern Japan. Jpn J Infect Dis 2006 59 : 367 9.
11. Shimoyama T, Fukuda S, Mikami T, Fukushi M, Munakata A. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J Gastroenterol 2004 39 : 927 30.
12. Isomoto H, Inoue K, Furusu H et al. High-dose rabeprazole-amoxicillin- metronidazole as second-line Helicobacter pylori infection. Aliment Pharmacol Ther 2003 18 : 101 7.
13. Miwa H, Nagahara A, Kurosawa A, et al. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 2003 17 : 1545 51.
14. Kato M, Yamaoka Y, Kim JJ et al. Regional difference in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agent Chemother 2000 44 : 2214 6.
15. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 2004 48 : 4843 7.
16. Nahar S, Mukhopadhyay AK, Khan R, et al. Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh. J Clin Microbiol 2004 42 : 4856 8.
17. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007 26 : 343 57.
18. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report. Gut 2007 56 : 772 81.
19. Okada M, Nishimura H, Kawashima M, Okabe N, Maeda K, Seo M, Ohkuma K, Takata T. A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Aliment Pharmacol Ther 1999 13 : 769 74.
20. Nagahara A, Miwa H, Ogawa K, et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000 5 : 88 93.
21. Nagahara A, Miwa H, Yamada T, Kurosawa A, Ohkura R, Sato N. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2001 15 : 417 21.
22. Neville PM, Everett S, Langworthy H, Tompkins D, Mapstone NP, Axon ATR, Moayyedi P. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999 13 : 497 501.
23. Okada M, Oki K, Shirotani T, et al. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol 1998 33 : 640 5.
24. Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/metronidazole/ omeprazole/clarithromycin: a new short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998 3 : 54 8.
25. Treiber G, Ammon S, Wittig J, Ammson S, Walker S, Doorn G, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002 162 : 153 60.
26. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Twelfth Informational Supplement M100-S12. Viillanova, PA : NCCLS, 2002.
27. + ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1994 660 : 211 20.
28. Neville PM, Everett S, Langworthy H, et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999 13 : 497 501.
29. Zullo A, De FV, Hassan C, Morini S, Vaira D. The sequential regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007 56 : 1353 7.
30. Van der Wouden EJ, Thijs JC, Van Zwet AA, Kooy A, Kleibeuker JH. The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. Aliment Pharmacol Ther 1999 13 : 297 302.
31. Andersen LP, Colding H, Kristiansen JE. Potentiation of the action of metronidazole on Helicobacter pylori by omeprazole and bismuth subcitrate. Int J Antimicrob Agents 2000 14 : 231 4.
32. Williamson R, Pipkin GA, Wood JR. New options in Helicobacter pylori eradication: efficacy, resistance and synergy. Scand J Gastroenterol Suppl 1998 225 : 36 40.
33. Cederbrant G, Kahlmeter G, Schalén C, Kamme C. Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori. J Antimicrob Chemother 1994 34 : 1025 9.
34. Svensson M, Ström M, Nilsson M, Sörberg M, Nilsson EL. Pharmacodynamic effects of nitroimidazole alone and in combination with clarithromycin on Helicobacter pylori. Antimicrob Agents Chemother 2002 46 : 2244 8.
35. Kato M. Helicobacter Research 2006 10 : 272 81. In Japanese.
36. Miwa H, Misawa H, Yamada T, Nagahara A, Ohtaka K, Sato N. Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection. Dig Dissci 2001 46 : 2445 50.
37. Kuwayama H, Asaka M, Fukuda Y, Aoyama Y, Hirai Y, Fujioka T. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. Aliment Pharmacol Ther 2007 25 : 1105 13.
38. Wilkinson RG. Drug metabolism and variability among patients in drug response. N Engl J Med 2005 352 : 2211 21.
39. Kato M, Yamaoka Y, Kim JJ, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000 44 : 2214 6.
40. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000 45 : 68 76.
41. Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs 2008 68 : 725 36.
42. Fischbach LA, van Zanten SV, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004 20 : 1071 82.